Walter M. Stadler to Everolimus
This is a "connection" page, showing publications Walter M. Stadler has written about Everolimus.
Connection Strength
0.604
-
Belzutifan versus Everolimus for Advanced Renal-Cell Carcinoma. N Engl J Med. 2024 Aug 22; 391(8):710-721.
Score: 0.238
-
Everolimus versus sunitinib for patients with metastatic non-clear cell renal cell carcinoma (ASPEN): a multicentre, open-label, randomised phase 2 trial. Lancet Oncol. 2016 Mar; 17(3):378-388.
Score: 0.131
-
FDG-PET as a predictive biomarker for therapy with everolimus in metastatic renal cell cancer. Cancer Med. 2013 Aug; 2(4):545-52.
Score: 0.110
-
Bevacizumab and everolimus in renal cancer: a rational way forward. J Clin Oncol. 2010 Nov 20; 28(33):e692-3; author reply e694.
Score: 0.091
-
Immunomodulatory Activity of Nivolumab in Metastatic Renal Cell Carcinoma. Clin Cancer Res. 2016 Nov 15; 22(22):5461-5471.
Score: 0.034